Total Payments
$467,977
2024 Payments
$75,660
Companies
3
Transactions
113
Payment Breakdown by Category
Consulting$375,004 (80.1%)
Research$92,973 (19.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $375,004 | 88 | 80.1% |
| Unspecified | $92,973 | 25 | 19.9% |
Payments by Type
General
$375,004
88 transactions
Research
$92,973
25 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $375,004 | 88 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $92,385 | 24 | $0 (2024) |
| Progenics Pharmaceuticals, Inc. | $588.00 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $75,660 | 13 | Regeneron Pharmaceuticals, Inc. ($75,660) |
| 2023 | $11,563 | 7 | Regeneron Pharmaceuticals, Inc. ($11,563) |
| 2021 | $88,609 | 27 | Merck Sharp & Dohme Corporation ($83,446) |
| 2020 | $54,273 | 20 | Merck Sharp & Dohme Corporation ($54,273) |
| 2019 | $57,553 | 23 | Merck Sharp & Dohme Corporation ($56,965) |
| 2018 | $129,302 | 12 | Merck Sharp & Dohme Corporation ($129,302) |
| 2017 | $51,018 | 11 | Merck Sharp & Dohme Corporation ($51,018) |
All Payment Transactions
113 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $300.00 | Research |
| Study: A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Pembrolizumab in Patients With Resectable Stage III and IV Melanoma • Category: ONCOLOGY | ||||||
| 11/19/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $3,840.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 10/18/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $6,240.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 09/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $5,220.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 08/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $3,360.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 06/21/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $10,560.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 06/21/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $6,420.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 06/21/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $5,880.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 06/07/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $5,640.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 04/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $10,200.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 03/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $9,000.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 03/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $4,620.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 02/07/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $4,380.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 12/12/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $4,380.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 11/07/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $2,460.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 10/10/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $1,740.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 10/10/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $1,200.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 10/10/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $700.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 08/10/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $120.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 04/13/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $962.50 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 12/09/2021 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $700.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 11/03/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $3,410.00 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2021 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $2,362.50 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 10/26/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,607.00 | General |
| Category: ONCOLOGY | ||||||
| 10/13/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $6,810.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | Regeneron Pharmaceuticals, Inc. | $86,923 | 19 |
| AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | Regeneron Pharmaceuticals, Inc. | $5,163 | 4 |
| IB12B PMR ICON | Progenics Pharmaceuticals, Inc. | $588.00 | 1 |
| A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Pembrolizumab in Patients With Resectable Stage III and IV Melanoma | Regeneron Pharmaceuticals, Inc. | $300.00 | 1 |
About Dr. Robert Smith, MD
Dr. Robert Smith, MD is a Diagnostic Radiology healthcare provider based in New Hyde Park, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2010. The National Provider Identifier (NPI) number assigned to this provider is 1346554136.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Smith, MD has received a total of $467,977 in payments from pharmaceutical and medical device companies, with $75,660 received in 2024. These payments were reported across 113 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($375,004).
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location New Hyde Park, NY
- Active Since 08/04/2010
- Last Updated 08/04/2010
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1346554136
Products in Payments
- KEYTRUDA (Biological) $316,806
- LIBTAYO (Biological) $87,223
- MK-4280 (Biological) $50,998
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in New Hyde Park
Dr. Jessica Ozsvath, M.d, M.D
Diagnostic Radiology — Payments: $16,100
Diagnostic Radiology $16,100
David Siegel, Md, MD
Diagnostic Radiology — Payments: $7,825
Diagnostic Radiology $7,825
Igor Lobko, Md, MD
Diagnostic Radiology — Payments: $7,394
Diagnostic Radiology $7,394
Barak Friedman, Md, MD
Diagnostic Radiology — Payments: $5,065
Diagnostic Radiology $5,065
William Weiner, D.o, D.O
Diagnostic Radiology — Payments: $1,096
Diagnostic Radiology $1,096
Dr. Shaya Ansari, Md, MD
Diagnostic Radiology — Payments: $872.06
Diagnostic Radiology $872.06